Literature DB >> 10556138

Increased risk for cancer following sarcoidosis.

J Askling1, J Grunewald, A Eklund, G Hillerdal, A Ekbom.   

Abstract

Little is known about the cancer risk following sarcoidosis. In a retrospective cohort study, we tested the hypothesis of an increased risk for malignant lymphomas, lung cancer as well as cancer in other organs frequently involved in sarcoidosis. Four hundred seventy-four patients from an incidence study 1966-1980 and 8,541 patients identified in the Swedish Inpatient Register (IPR) 1964-1994 were linked to the Cancer Register, the Register of Causes of Death, and the Register of Total Population. Relative risks were estimated using standardized incidence ratios (SIR). The overall relative risks for cancer were similar and elevated in both cohorts (IPR presented), SIR = 1.3; 95% confidence interval (CI) 1.2 to 1.4. For lung cancer and non-Hodgkin's lymphoma, the relative risk was doubled during the first decade of follow-up. Thereafter, the risk for lung cancer was significantly decreased whereas the risk for non-Hodgkin's lymphoma equaled unity. Throughout follow-up, elevated risks were found for melanoma (SIR = 1.6; 95% CI 1.0 to 2.3) and nonmelanoma skin cancer (SIR = 2.8; 95% CI 2.0 to 3.8). An increased risk was also found for liver cancer (SIR = 1.4; 95% CI 0.8 to 2.2). Thus, sarcoidosis appears to be associated with a significantly increased risk for cancer in affected organs. Chronic inflammation is a putative mediator of this risk.

Entities:  

Mesh:

Year:  1999        PMID: 10556138     DOI: 10.1164/ajrccm.160.5.9904045

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  63 in total

1.  Two cases of sarcoidosis-lymphoma syndrome.

Authors:  Nada Suvajdzic; Branislava Milenkovic; Maja Perunicic; Jelena Stojsic; Snezana Jankovic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

2.  Sarcoidosis and the occurrence of malignant diseases.

Authors:  Norbert Blank; Hanns-Martin Lorenz; Anthony D Ho; Mathias Witzens-Harig
Journal:  Rheumatol Int       Date:  2014-03-23       Impact factor: 2.631

3.  Concomitant sarcoidosis and papillary thyroid cancer with severe hypercalcaemia as the main symptom.

Authors:  Mikael Groth Riis; Kasper Svendsen Juhl; Jens Meldgaard Bruun
Journal:  BMJ Case Rep       Date:  2018-06-08

Review 4.  A case of pulmonary sarcoidosis preceding polycythemia vera with literature review.

Authors:  Daniela Tirotta; Vittorio Durante
Journal:  Rheumatol Int       Date:  2010-03-13       Impact factor: 2.631

5.  Hilar and mediastinal sarcoid-like reaction after the treatment of malignant tumors: imaging features and natural course on 18F-FDG-PET/CT.

Authors:  Yo Kaneko; Hiroki Kato; Masayuki Matsuo
Journal:  Jpn J Radiol       Date:  2018-10-15       Impact factor: 2.374

6.  Chapter 6: Lung cancer in never smokers: epidemiology and risk prediction models.

Authors:  William J McCarthy; Rafael Meza; Jihyoun Jeon; Suresh H Moolgavkar
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

7.  A cross-talk between NFAT and NF-κB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells.

Authors:  Tongjian Cai; Xueyong Li; Jin Ding; Wenjing Luo; Jingxia Li; Chuanshu Huang
Journal:  Curr Cancer Drug Targets       Date:  2011-06       Impact factor: 3.428

8.  Hyaline-Vascular Type Castleman's Disease, Sarcoidosis, and Crohns Disease.

Authors:  Arjun Gupta; Balaji Ayyar; Hamid Zia; Weina Chen; Samar Harris; Harris V Naina
Journal:  Indian J Hematol Blood Transfus       Date:  2015-09-01       Impact factor: 0.900

Review 9.  Epidemiology and clinical characteristics of sarcoidosis: an update from a population-based cohort study from Olmsted County, Minnesota.

Authors:  P Ungprasert; C S Crowson; E L Matteson
Journal:  Reumatismo       Date:  2017-05-22

10.  The diagnostic challenge of mediastinal sarcoidosis accompanying esophageal cancer.

Authors:  Matthias Schauer; Joerg Theisen
Journal:  World J Surg Oncol       Date:  2010-03-12       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.